Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Germany,
Strahlenther Onkol. 2012 Jan;188(1):56-61. doi: 10.1007/s00066-011-0017-8. Epub 2011 Dec 23.
The goal was to retrospectively review the outcome of patients with cervical lymph node metastases of squamuos cell carcinoma of unknown primary site (CUP) treated with radio(chemo)therapy.
A total of 65 patients with CUP N1-3, M0, treated between 1988 and 2009 were evaluated: 61 patients underwent surgical resection followed by postoperative radio(chemo)therapy, 4 patients received definitive radiochemotherapy. Radiotherapy of bilateral neck nodes + the parapharyngeal region (COMP-RT) was performed in 48 patients (80%) and a unilateral radiotherapy of lymph nodes (UL-RT) in 17 patients (20%).
After a median follow-up time of 64 months (range 3-219 months), the estimated 2- and 5-year overall survival (OS) rates were 71 ± 6% and 48 ± 7%, respectively. The recurrent free survival (RFS) rate at 2- and 5-years was 58 ± 6% and 48% ± 7%, respectively. Extracapsular spread, resection status (R0 vs. R1/R2), neck lymph node level (I-III vs. IV-V), and Karnofsky index (60-70 vs. 80-100) were significant prognostic factors for OS and RFS in the univariate analysis. Lower nodal stage (N1/N2a vs. N2b/N2c/N3) was significantly associated with a better OS. Resection status and involvement of lymph node level IV significantly affected the OS and RFS in the multivariate analysis. COMP-RT or concurrent chemotherapy was not associated with a better OS or RFS.
An advantage of comprehensive radiotherapy or radiochemotherapy compared with unilateral radiotherapy of lymph nodes was not observed.
回顾分析治疗不明原发灶的颈部淋巴结转移鳞癌(CUP)患者的治疗结果。
回顾性分析 1988 年至 2009 年期间收治的 65 例颈淋巴结转移的 CUP(N1-3,M0)患者。61 例行手术切除联合术后放化疗,4 例行根治性放化疗。48 例患者接受双侧颈部淋巴结+咽旁区(COMP-RT)放疗(80%),17 例患者接受单侧颈部淋巴结放疗(UL-RT)(20%)。
中位随访时间为 64 个月(3-219 个月),2 年和 5 年总生存率(OS)分别为 71%±6%和 48%±7%,2 年和 5 年无复发生存率(RFS)分别为 58%±6%和 48%±7%。单因素分析显示,包膜外侵犯、手术切缘(R0 与 R1/R2)、颈部淋巴结水平(I-III 与 IV-V)、卡氏功能状态评分(60-70 与 80-100)是影响 OS 和 RFS 的预后因素。淋巴结分期(N1/N2a 与 N2b/N2c/N3)越低,OS 越好。手术切缘和 IV 区淋巴结受累是影响 OS 和 RFS 的独立预后因素。COMP-RT 或同期化疗与 OS 和 RFS 无关。
与单侧颈部淋巴结放疗相比,综合放疗或放化疗并未显示出优势。